Astrajenca CEO was doubled at us in rumors of the shift list

Astragenecca Chief Executive Officer Pascal Soriot on Tuesday reiterated the Pharmaceutical firm’s commitment to the US market and is planning to replace the status of your list.

Soriot said that there were many reasons for living in the United States in the United States, saying that it is “transferring the product rapidly” in Atlantic.

“We have a lot of reasons for being here (in the US),” Soriot told the media during the call of earnings.

He said, “This country (America) will represent our 50% of our revenue till 2030. We have thousands of employees across the country.”

The second quarter earnings report on Tuesday states that the AST Strezenca is doubled in the US market, saying it is the ambition of the country to earn $ 80 billion by the end of the decade.

“We are a global company but we are definitely very present, present and rooted in the United States,” Soriot said, there is plan to be self -sufficient soon.

The company said it was a plan last week Billion Invest in $ 50 billion In enhancing its American production and research capabilities. This is the latest pharmaceutical firm in the wake of the US trade fees and the President Donald Trump appealed to the manufacturing again to replace the manufacturing.

“Our investment is reflecting our faith in this country’s growth. We want to contribute to it,” Soriot said that he had met the Trump administration to discuss the growth plans in the sector.

“The United States has actually led in biofurmasutical innovation nowadays,” he further said that he criticized the failure of Europe’s development. “Today, very little goes out of Europe.”

Earlier this month, Times reported that the firm could move its list from London to the United States, what the analysts said Hunger In the UK’s public market.

At that time, Astrajenke refused to comment on the report. However, Chief Financial Officer Acharana Sarin said on Tuesday that the company is “committed” to UK

The demand for cancer and biofermasutical products on Tuesday made Astragenek earned more than expected on Tuesday.

Anglo-Sideish Pharma firm reported $ 5.46 billion in a three-month period of three months beyond the LSEG survey.

The quarterly adjusted core operating profits came to $ 8.88 billion compared to $ 4.48 billion.

The FTSE100 company maintained the entire year estimates to increase the highest single-digit percentage and per share core earnings to increase the double-digit percentage.

This comes as it faces the European pharmaceutical field Expected 15% size As part of the broad Eu-cus trade agreement on the US imports. Analysts warned that if the rate, if the rate is charged by 15% or higher, European companies and blocks could disrupt the widespread economy.

Nevertheless, Astragenakeka suggested in April that if the US rates on European pharma products are filed against other sectors, they would maintain their 2025 sales guidance.

“This issue of rates is not a matter of really affecting you,” said Soriot.